Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc reported strong first quarter 2026 results driven by ARCALYST. Net product revenue reached $214.3 million, representing 56% year-over-year growth, and total revenue was $214.3 million versus $137.8 million a year earlier. Net income rose to $22.6 million, up from $8.5 million, with diluted earnings per share increasing to $0.27 from $0.11.
The company raised its 2026 ARCALYST net sales guidance to a range of $930–$945 million, up from $900–$920 million, citing expanding adoption in recurrent pericarditis. Cash, cash equivalents, and short-term investments increased to $468.1 million as of March 31, 2026. Kiniksa highlighted portfolio progress, including Phase 2 KPL-387 recurrent pericarditis data expected in the second half of 2026 and initiation of a Phase 3 pivotal trial by year-end, as well as ongoing preclinical work on KPL-1161.
Kiniksa Pharmaceuticals International, plc is asking shareholders to vote on eight proposals at its 2026 Annual Meeting on May 29, 2026 at its London offices. Holders of Class A ordinary shares have one vote per share and Class B ordinary shares have ten votes per share as of the April 6, 2026 record date.
Proposals include re-electing three Class II directors until the 2029 meeting, appointing and ratifying PricewaterhouseCoopers LLP as UK statutory auditors and US independent registered public accounting firm, authorizing the Audit Committee to set PwC’s UK audit fees, and receiving the UK statutory annual report for 2025.
Shareholders are also being asked to approve, on an advisory basis, the UK Statutory Directors’ Remuneration Report, approve an updated UK Remuneration Policy governing director pay for up to three years, and cast a non-binding Say-on-Pay vote on compensation for named executive officers.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported an open-market sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. After this transaction, he directly holds 27,418 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Kiniksa Pharmaceuticals International, plc chief operating officer Moat Ross reported an open-market sale of 1,703 Class A Ordinary Shares on April 9, 2026 at $46.69 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan entered on November 13, 2024, and Ross now directly holds 12,029 shares.
Kiniksa Pharmaceuticals, Ltd. Form 144 notice lists proposed sales of Class A ordinary shares tied to equity compensation and a restricted stock lapse. The excerpt shows a 04/07/2026 restricted-stock lapse and a proposed sale quantity listed as 79,513.00, plus a recent reported sale of 114,989.00 shares on 04/06/2026.
Kiniksa Pharmaceuticals International, plc filed a Form 144 reporting proposed dispositions of Class A ordinary shares. The filing lists a total of 6,625 shares tied to restricted stock lapses on 04/01/2026 (4,359 shares) and 04/07/2026 (2,266 shares).
Kiniksa Pharmaceuticals International, plc chief strategy officer Eben Tessari exercised Restricted Share Units into common shares and had shares withheld for taxes. On April 7, 2026, 2,726 RSUs were converted into 2,726 Class A Ordinary Shares. Of these, 846 shares at $48.94 per share were withheld to satisfy tax obligations, leaving Tessari with 23,130 Class A Ordinary Shares held directly. Each RSU represents a right to receive one Class A Ordinary Share and the RSU grant vests in four equal annual installments starting on April 7, 2023, over a four-year period.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa exercised 2,694 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Each RSU converts into one share and is part of a grant that vests in four equal annual installments starting April 7, 2022.
To cover tax obligations from this vesting, 1,303 Class A Ordinary Shares were withheld at a price of $48.94 per share, rather than sold in the open market. After these compensation-related transactions, Ragosa directly holds 16,154 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc Chairman & CEO Sanj K. Patel reported multiple equity transactions in the company’s Class A Ordinary Shares. On April 6, 2026, he exercised options for 7,278 shares at $10.36 per share and sold 7,278 shares at a weighted average price of about $50.01 in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.
On April 7, 2026, 9,991 Restricted Share Units converted into the same number of Class A Ordinary Shares, credited to The Patel Family Irrevocable Trust of 2025. Of these, 4,831 shares were withheld at $48.94 per share to cover tax obligations, leaving 76,174 shares in that trust. Additional indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.